{
  "_originalData": {
    "identity": {
      "bacteriumName": "Enterobacter cloacae complex",
      "aliases": [
        "Enterobacter spp."
      ],
      "lastUpdated": "2025-01-02",
      "clsiCategory": "Enterobacterales (excluding Salmonella/Shigella)",
      "classification": {
        "gramStain": "Negative",
        "morphology": "Bacillus",
        "respiration": "Facultative Anaerobe",
        "notes": []
      },
      "strainDetails": [
        {
          "type": "Complex Member",
          "value": "Enterobacter cloacae",
          "notes": ""
        },
        {
          "type": "Complex Member",
          "value": "Enterobacter hormaechei",
          "notes": ""
        }
      ],
      "biochemicalTests": "Gram-negative rod, motile, lactose fermenter, indole –, VP +, citrate +, ornithine decarboxylase +, arginine dihydrolase +."
    },
    "clinicalProfile": {
      "summary": "The Enterobacter cloacae complex causes a variety of infections in both normal and immunocompromised hosts and is a frequent cause of nosocomial infections, including bacteremia, pneumonia, and intra-abdominal infections.",
      "pathophysiologyPearls": [
        "Exposure to 3rd-generation cephalosporins can select for de-repressed ampC mutants, with emergence of resistance during therapy in 5-20% of treatment courses."
      ],
      "keySignsAndSymptoms": [],
      "clinicalSyndromes": [
        {
          "syndromeName": "Systemic Infections",
          "description": "Can cause bacteremia, pneumonia, intra-abdominal infections, and skin and soft tissue infections."
        }
      ],
      "stagesOfIllness": [],
      "highRiskPopulations": [
        "Hospitalized patients",
        "Immunocompromised hosts"
      ],
      "transmissionVectors": [],
      "prognosisNotes": [
        "Emergence of resistance during therapy with 3rd-generation cephalosporins occurs in 5-20% of treatment courses due to de-repression of the ampC gene."
      ]
    },
    "resistanceProfile": {
      "groupIntrinsicResistance": [],
      "intrinsicResistance": [],
      "majorMechanisms": [
        {
          "mechanismName": "AmpC (Chromosomal)",
          "mechanismType": "Cephalosporinase",
          "description": "Virtually all isolates carry an inducible, chromosomal ampC gene that is normally repressed. It is not inhibited by clavulanate, sulbactam, or tazobactam, but is inhibited by avibactam."
        },
        {
          "mechanismName": "ESBL",
          "mechanismType": "Beta-lactamase",
          "description": "Can acquire plasmid-encoded Extended-Spectrum Beta-Lactamases, which are not readily distinguishable phenotypically from de-repressed AmpC."
        },
        {
          "mechanismName": "Carbapenemases",
          "mechanismType": "Beta-lactamase",
          "description": "Can acquire plasmid-encoded carbapenemases, including serine carbapenemases (KPC) and metallo-beta-lactamases (MBL)."
        },
        {
          "mechanismName": "Other MDR Mechanisms",
          "mechanismType": "Multiple",
          "description": "Multi-drug resistance can also be mediated by over-expression of drug efflux pumps, target alterations, and outer membrane protein mutations affecting drug permeability."
        }
      ],
      "clinicalAlerts": [
        {
          "alertTitle": "Inducible AmpC Resistance",
          "details": "Exposure to 3rd-generation cephalosporins (e.g., ceftriaxone, ceftazidime) can select for de-repressed mutants that over-express AmpC, leading to clinical failure even if initial testing shows susceptibility. These agents should be avoided for serious infections."
        }
      ]
    },
    "treatment": {
      "generalNotes": [
        "Recommendations are for treatment of moderately severe or severe infections.",
        "For uncomplicated UTI, options include fluoroquinolones, TMP-SMX, or nitrofurantoin if susceptible. Third-generation cephalosporins can be used for uncomplicated UTI but should be avoided otherwise."
      ],
      "drugsToAvoid": [
        {
          "drugOrClass": "3rd Generation Cephalosporins (Ceftriaxone, Ceftazidime, etc.)",
          "condition": "Serious infections",
          "reason": "High risk of selecting for de-repressed AmpC mutants and subsequent treatment failure."
        },
        {
          "drugOrClass": "Piperacillin-tazobactam",
          "condition": "Serious infections",
          "reason": "Risk of clinical failure despite potential in-vitro susceptibility, especially for ESBL-producers."
        },
        {
          "drugOrClass": "Meropenem + Polymyxin",
          "condition": "All infections",
          "reason": "Combination therapy is not recommended based on a failed randomized controlled trial (Lancet Infect Dis 2018;18:391)."
        }
      ],
      "adjunctiveTherapies": [],
      "regimens": [
        {
          "context": {
            "type": "Empiric",
            "condition": "Systemic Infection (Low Local ESBL Rate <10-15%)",
            "patientPopulation": [
              "Adult"
            ],
            "isolateSource": null
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Concurrent",
              "steps": [
                {
                  "step": 1,
                  "duration": "Variable",
                  "drugs": [
                    {
                      "drugName": "Cefepime",
                      "dose": "1-2 gm",
                      "route": "IV",
                      "frequency": "q8-12h",
                      "comments": "Infuse over 3 hours."
                    },
                    {
                      "drugName": "Ciprofloxacin",
                      "dose": "400 mg",
                      "route": "IV",
                      "frequency": "q12h",
                      "comments": ""
                    },
                    {
                      "drugName": "Levofloxacin",
                      "dose": "750 mg",
                      "route": "IV",
                      "frequency": "q24h",
                      "comments": ""
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Empiric",
            "condition": "Systemic Infection (High Local ESBL Rate >15% or Severe Illness)",
            "patientPopulation": [
              "Adult"
            ],
            "isolateSource": null
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Concurrent",
              "steps": [
                {
                  "step": 1,
                  "duration": "Variable",
                  "drugs": [
                    {
                      "drugName": "Meropenem",
                      "dose": "1-2 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": ""
                    },
                    {
                      "drugName": "Ertapenem",
                      "dose": "1 gm",
                      "route": "IV",
                      "frequency": "q24h",
                      "comments": ""
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "ESBL or AmpC Overproducer",
            "patientPopulation": [
              "Adult"
            ],
            "isolateSource": null
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Concurrent",
              "steps": [
                {
                  "step": 1,
                  "duration": "Variable",
                  "drugs": [
                    {
                      "drugName": "Meropenem",
                      "dose": "1-2 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Consider 2 gm infused over 3 hours for more serious infections."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Alternative (If susceptible)",
              "strategy": "Concurrent",
              "steps": [
                {
                  "step": 1,
                  "duration": "Variable",
                  "drugs": [
                    {
                      "drugName": "Ciprofloxacin",
                      "dose": "400 mg",
                      "route": "IV",
                      "frequency": "q12h",
                      "comments": ""
                    },
                    {
                      "drugName": "Levofloxacin",
                      "dose": "750 mg",
                      "route": "IV",
                      "frequency": "q24h",
                      "comments": ""
                    },
                    {
                      "drugName": "TMP-SMX",
                      "dose": "10 mg/kg/day (TMP component)",
                      "route": "IV",
                      "frequency": "in 2-3 divided doses",
                      "comments": ""
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "KPC Producer (Carbapenem-Resistant)",
            "patientPopulation": [
              "Adult"
            ],
            "isolateSource": null
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Concurrent",
              "steps": [
                {
                  "step": 1,
                  "duration": "Variable",
                  "drugs": [
                    {
                      "drugName": "Ceftazidime-avibactam",
                      "dose": "2.5 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Infuse over 3 hours."
                    },
                    {
                      "drugName": "Meropenem-vaborbactam",
                      "dose": "4 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Infuse over 3 hours."
                    },
                    {
                      "drugName": "Imipenem-cilastatin-relebactam",
                      "dose": "1.25 gm",
                      "route": "IV",
                      "frequency": "q6h",
                      "comments": "Infuse over 30 min. For CrCl > 90 mL/min."
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "Metallo-beta-lactamase (MBL) Producer",
            "patientPopulation": [
              "Adult"
            ],
            "isolateSource": null
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Concurrent",
              "steps": [
                {
                  "step": 1,
                  "duration": "Variable",
                  "drugs": [
                    {
                      "drugName": "Ceftazidime-avibactam",
                      "dose": "2.5 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Infuse over 3 hours."
                    },
                    {
                      "drugName": "Aztreonam",
                      "dose": "2 gm",
                      "route": "IV",
                      "frequency": "q6h",
                      "comments": "Infuse over 3 hours."
                    }
                  ]
                }
              ],
              "notes": [
                "This combination is recommended because Aztreonam is not hydrolyzed by MBLs, while Avibactam protects Aztreonam from co-produced ESBLs or AmpC enzymes."
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Concurrent",
              "steps": [
                {
                  "step": 1,
                  "duration": "Variable",
                  "drugs": [
                    {
                      "drugName": "Cefiderocol",
                      "dose": "2 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Infuse over 3 hours."
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "condition": "ESBL Producer",
            "patientPopulation": [
              "Adult"
            ],
            "isolateSource": "Urinary Tract"
          },
          "recommendations": [
            {
              "preference": "Alternative",
              "strategy": "Concurrent",
              "steps": [
                {
                  "step": 1,
                  "duration": "Variable",
                  "drugs": [
                    {
                      "drugName": "Cefepime-enmetazobactam",
                      "dose": "2.5 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Recently FDA approved for complicated UTIs, including ESBL producers."
                    },
                    {
                      "drugName": "Plazomicin",
                      "dose": "15 mg/kg",
                      "route": "IV",
                      "frequency": "q24h",
                      "comments": "For complicated UTIs."
                    },
                    {
                      "drugName": "Fosfomycin",
                      "dose": "3 gm",
                      "route": "PO",
                      "frequency": "x 1 dose",
                      "comments": "For uncomplicated cystitis only."
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "laboratoryProfile": {
      "testingIndications": [],
      "methodologyNotes": [
        "For Polymyxins, disk diffusion and gradient diffusion methods should not be performed; MIC testing is required."
      ],
      "recommendedPanel": [
        "Cefepime should be considered a Tier 1 agent for testing and/or reporting."
      ],
      "specialTests": [],
      "reportingRules": [
        {
          "ruleType": "Conditional",
          "drug": "Cefepime",
          "condition": "Isolate demonstrates carbapenemase production.",
          "details": "Cefepime S/SDD results should be suppressed or edited and reported as resistant."
        }
      ],
      "antimicrobialBreakpoints": [
        {
          "tier": 1,
          "tierDescription": "Appropriate for routine, primary testing and reporting.",
          "agents": [
            {
              "agentName": "Ampicillin",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "10 µg",
                    "s_breakpoint": "≥ 17",
                    "i_breakpoint": "14–16",
                    "r_breakpoint": "≤ 13"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 8",
                    "i_breakpoint": "16",
                    "r_breakpoint": "≥ 32"
                  },
                  "comments": [
                    "Results of ampicillin testing can be used to predict results for amoxicillin."
                  ]
                }
              ]
            },
            {
              "agentName": "Cefazolin",
              "breakpointSets": [
                {
                  "condition": "Urine Only (Uncomplicated UTI)",
                  "diskDiffusion": {
                    "diskContent": "30 µg",
                    "s_breakpoint": "≥ 15",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≤ 14"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 16",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≥ 32"
                  },
                  "comments": [
                    "Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."
                  ]
                }
              ]
            },
            {
              "agentName": "Amoxicillin-clavulanate",
              "breakpointSets": [
                {
                  "condition": "Uncomplicated UTI only",
                  "diskDiffusion": {
                    "diskContent": "20/10 µg",
                    "s_breakpoint": "≥ 18",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≤ 17"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 8/4",
                    "i_breakpoint": "16/4",
                    "r_breakpoint": "≥ 32/4"
                  },
                  "comments": []
                }
              ]
            },
            {
              "agentName": "Piperacillin-tazobactam",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "100/10 µg",
                    "s_breakpoint": "≥ 25",
                    "i_breakpoint": "21–24",
                    "r_breakpoint": "≤ 20"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 8/4",
                    "i_breakpoint": "16/4",
                    "r_breakpoint": "≥ 32/4"
                  },
                  "comments": []
                }
              ]
            }
          ]
        },
        {
          "tier": 2,
          "tierDescription": "Appropriate for routine, primary testing, may be reported following cascade reporting rules.",
          "agents": [
            {
              "agentName": "Cefepime",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "30 µg",
                    "s_breakpoint": "≥ 25",
                    "i_breakpoint": "19–24",
                    "r_breakpoint": "≤ 18"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 4",
                    "i_breakpoint": "8",
                    "r_breakpoint": "≥ 16"
                  },
                  "comments": [
                    "Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."
                  ]
                }
              ]
            },
            {
              "agentName": "Ertapenem",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "10 µg",
                    "s_breakpoint": "≥ 22",
                    "i_breakpoint": "19–21",
                    "r_breakpoint": "≤ 18"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 0.5",
                    "i_breakpoint": "1",
                    "r_breakpoint": "≥ 2"
                  },
                  "comments": []
                }
              ]
            },
            {
              "agentName": "Meropenem",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "10 µg",
                    "s_breakpoint": "≥ 23",
                    "i_breakpoint": "20–22",
                    "r_breakpoint": "≤ 19"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 1",
                    "i_breakpoint": "2",
                    "r_breakpoint": "≥ 4"
                  },
                  "comments": []
                }
              ]
            }
          ]
        },
        {
          "tier": 3,
          "tierDescription": "Appropriate for high-risk MDRO patients, subject to cascade reporting.",
          "agents": [
            {
              "agentName": "Ceftazidime-avibactam",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "30/20 µg",
                    "s_breakpoint": "≥ 21",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≤ 20"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 8/4",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≥ 16/4"
                  },
                  "comments": [
                    "Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."
                  ]
                }
              ]
            },
            {
              "agentName": "Meropenem-vaborbactam",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "20/10 µg",
                    "s_breakpoint": "≥ 18",
                    "i_breakpoint": "15–17",
                    "r_breakpoint": "≤ 14"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 4/8",
                    "i_breakpoint": "8/8",
                    "r_breakpoint": "≥ 16/8"
                  },
                  "comments": [
                    "If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."
                  ]
                }
              ]
            }
          ]
        },
        {
          "tier": 4,
          "tierDescription": "May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",
          "agents": [
            {
              "agentName": "Aztreonam",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "30 µg",
                    "s_breakpoint": "≥ 21",
                    "i_breakpoint": "18–20",
                    "r_breakpoint": "≤ 17"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 4",
                    "i_breakpoint": "8",
                    "r_breakpoint": "≥ 16"
                  },
                  "comments": []
                }
              ]
            },
            {
              "agentName": "Ceftriaxone",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "30 µg",
                    "s_breakpoint": "≥ 26",
                    "i_breakpoint": "20–22",
                    "r_breakpoint": "≤ 19"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 1",
                    "i_breakpoint": "2",
                    "r_breakpoint": "≥ 4"
                  },
                  "comments": []
                }
              ]
            },
            {
              "agentName": "Colistin or Polymyxin B",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": null,
                  "mic": {
                    "s_breakpoint": "≤ 2",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≥ 4"
                  },
                  "comments": [
                    "Disk diffusion and gradient diffusion methods should not be performed."
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "additionalInformation": {
      "diagnosticNotes": null,
      "preventionAndScreening": [],
      "treatmentLifecycle": [],
      "antimicrobialStewardship": [
        "Carbapenems should be reserved for mixed infections or for treatment of confirmed ESBL-producing strains.",
        "Novel beta-lactam/beta-lactamase inhibitor combinations (e.g., Ceftazidime-avibactam) should be reserved for documented carbapenemase-producing organisms."
      ],
      "drugSpecificPearls": [
        {
          "drugName": "Cefepime",
          "pearl": "Cefepime is a weak inducer of chromosomal AmpC and more resistant to its hydrolysis than other cephalosporins. For strains with MICs of 4-8 mcg/ml, dose-dependent susceptibility is noted; the recommended dose is 2 gm IV q8h infused over 3 hours."
        },
        {
          "drugName": "Cefiderocol",
          "pearl": "FDA-approved for cUTI with limited options. An open-label trial in patients with serious carbapenem-resistant infections showed numerically higher all-cause mortality with cefiderocol vs. best available therapy, warranting caution."
        },
        {
          "drugName": "Ceftazidime-avibactam + Aztreonam",
          "pearl": "The rationale for this combination for MBL producers is that Aztreonam is stable against MBLs, and Avibactam protects Aztreonam from co-produced serine beta-lactamases (ESBL, AmpC, KPC)."
        },
        {
          "drugName": "Fosfomycin (IV)",
          "pearl": "In the US, it may be possible to obtain IV Fosfomycin as a single-patient emergency IND from the FDA's Division of Anti-infective Products."
        }
      ],
      "guidelineReferences": [
        {
          "source": "IDSA 2024",
          "citation": "Updated 2024 IDSA Guidelines on treatment of ESBL, AmpC, and carbapenemase producers.",
          "summaryOrNote": "Provides comprehensive guidance on treating resistant gram-negative infections."
        },
        {
          "source": "Clinical Infectious Diseases",
          "citation": "Clin Infect Dis 2019;69:1446",
          "summaryOrNote": "Primer on AmpC beta-lactamases."
        }
      ]
    }
  },
  "_metadata": {
    "originalKeys": [
      "identity",
      "clinicalProfile",
      "resistanceProfile",
      "treatment",
      "laboratoryProfile",
      "additionalInformation"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.311Z",
    "sourceFormat": "modern"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "identity.bacteriumName"
      ],
      "value": "Enterobacter cloacae complex"
    },
    "aliases": {
      "sources": [
        "identity.aliases"
      ],
      "value": [
        "Enterobacter spp."
      ]
    },
    "lastUpdated": {
      "sources": [
        "identity.lastUpdated"
      ],
      "value": "2025-01-02"
    },
    "classification": {
      "sources": [
        "identity.classification"
      ],
      "value": {
        "gramStain": "Negative",
        "morphology": "Bacillus",
        "respiration": "Facultative Anaerobe",
        "notes": []
      }
    }
  },
  "clinicalInformation": {
    "sources": [
      "clinicalProfile"
    ],
    "value": {
      "summary": "The Enterobacter cloacae complex causes a variety of infections in both normal and immunocompromised hosts and is a frequent cause of nosocomial infections, including bacteremia, pneumonia, and intra-abdominal infections.",
      "pathophysiologyPearls": [
        "Exposure to 3rd-generation cephalosporins can select for de-repressed ampC mutants, with emergence of resistance during therapy in 5-20% of treatment courses."
      ],
      "keySignsAndSymptoms": [],
      "clinicalSyndromes": [
        {
          "syndromeName": "Systemic Infections",
          "description": "Can cause bacteremia, pneumonia, intra-abdominal infections, and skin and soft tissue infections."
        }
      ],
      "stagesOfIllness": [],
      "highRiskPopulations": [
        "Hospitalized patients",
        "Immunocompromised hosts"
      ],
      "transmissionVectors": [],
      "prognosisNotes": [
        "Emergence of resistance during therapy with 3rd-generation cephalosporins occurs in 5-20% of treatment courses due to de-repression of the ampC gene."
      ]
    }
  },
  "resistanceInformation": {
    "sources": [
      "resistanceProfile"
    ],
    "value": {
      "groupIntrinsicResistance": [],
      "intrinsicResistance": [],
      "majorMechanisms": [
        {
          "mechanismName": "AmpC (Chromosomal)",
          "mechanismType": "Cephalosporinase",
          "description": "Virtually all isolates carry an inducible, chromosomal ampC gene that is normally repressed. It is not inhibited by clavulanate, sulbactam, or tazobactam, but is inhibited by avibactam."
        },
        {
          "mechanismName": "ESBL",
          "mechanismType": "Beta-lactamase",
          "description": "Can acquire plasmid-encoded Extended-Spectrum Beta-Lactamases, which are not readily distinguishable phenotypically from de-repressed AmpC."
        },
        {
          "mechanismName": "Carbapenemases",
          "mechanismType": "Beta-lactamase",
          "description": "Can acquire plasmid-encoded carbapenemases, including serine carbapenemases (KPC) and metallo-beta-lactamases (MBL)."
        },
        {
          "mechanismName": "Other MDR Mechanisms",
          "mechanismType": "Multiple",
          "description": "Multi-drug resistance can also be mediated by over-expression of drug efflux pumps, target alterations, and outer membrane protein mutations affecting drug permeability."
        }
      ],
      "clinicalAlerts": [
        {
          "alertTitle": "Inducible AmpC Resistance",
          "details": "Exposure to 3rd-generation cephalosporins (e.g., ceftriaxone, ceftazidime) can select for de-repressed mutants that over-express AmpC, leading to clinical failure even if initial testing shows susceptibility. These agents should be avoided for serious infections."
        }
      ]
    }
  },
  "treatmentData": {
    "treatmentData": {
      "_treatmentMetadata": {
        "originalFormat": "modern"
      },
      "standardizedRegimens": [
        {
          "regimenId": "modern-0-0-0",
          "extractedFrom": "treatment.regimens[0].recommendations[0].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Systemic Infection (Low Local ESBL Rate <10-15%)",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adult"
              ],
              "labFindings": null
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Cefepime",
              "dose": "1-2 gm",
              "route": "IV",
              "frequency": "q8-12h",
              "duration": "Variable",
              "comments": "Infuse over 3 hours.",
              "originalText": "Cefepime 1-2 gm IV q8-12h"
            },
            {
              "drugName": "Ciprofloxacin",
              "dose": "400 mg",
              "route": "IV",
              "frequency": "q12h",
              "duration": "Variable",
              "comments": "",
              "originalText": "Ciprofloxacin 400 mg IV q12h"
            },
            {
              "drugName": "Levofloxacin",
              "dose": "750 mg",
              "route": "IV",
              "frequency": "q24h",
              "duration": "Variable",
              "comments": "",
              "originalText": "Levofloxacin 750 mg IV q24h"
            }
          ]
        },
        {
          "regimenId": "modern-1-0-0",
          "extractedFrom": "treatment.regimens[1].recommendations[0].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Systemic Infection (High Local ESBL Rate >15% or Severe Illness)",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adult"
              ],
              "labFindings": null
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Meropenem",
              "dose": "1-2 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "Variable",
              "comments": "",
              "originalText": "Meropenem 1-2 gm IV q8h"
            },
            {
              "drugName": "Ertapenem",
              "dose": "1 gm",
              "route": "IV",
              "frequency": "q24h",
              "duration": "Variable",
              "comments": "",
              "originalText": "Ertapenem 1 gm IV q24h"
            }
          ]
        },
        {
          "regimenId": "modern-2-0-0",
          "extractedFrom": "treatment.regimens[2].recommendations[0].steps[0]",
          "context": {
            "type": "directed",
            "condition": "ESBL or AmpC Overproducer",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adult"
              ],
              "labFindings": null
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Meropenem",
              "dose": "1-2 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "Variable",
              "comments": "Consider 2 gm infused over 3 hours for more serious infections.",
              "originalText": "Meropenem 1-2 gm IV q8h"
            }
          ]
        },
        {
          "regimenId": "modern-2-1-0",
          "extractedFrom": "treatment.regimens[2].recommendations[1].steps[0]",
          "context": {
            "type": "directed",
            "condition": "ESBL or AmpC Overproducer",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adult"
              ],
              "labFindings": null
            }
          },
          "preference": "alternative (if susceptible)",
          "drugs": [
            {
              "drugName": "Ciprofloxacin",
              "dose": "400 mg",
              "route": "IV",
              "frequency": "q12h",
              "duration": "Variable",
              "comments": "",
              "originalText": "Ciprofloxacin 400 mg IV q12h"
            },
            {
              "drugName": "Levofloxacin",
              "dose": "750 mg",
              "route": "IV",
              "frequency": "q24h",
              "duration": "Variable",
              "comments": "",
              "originalText": "Levofloxacin 750 mg IV q24h"
            },
            {
              "drugName": "TMP-SMX",
              "dose": "10 mg/kg/day (TMP component)",
              "route": "IV",
              "frequency": "in 2-3 divided doses",
              "duration": "Variable",
              "comments": "",
              "originalText": "TMP-SMX 10 mg/kg/day (TMP component) IV in 2-3 divided doses"
            }
          ]
        },
        {
          "regimenId": "modern-3-0-0",
          "extractedFrom": "treatment.regimens[3].recommendations[0].steps[0]",
          "context": {
            "type": "directed",
            "condition": "KPC Producer (Carbapenem-Resistant)",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adult"
              ],
              "labFindings": null
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Ceftazidime-avibactam",
              "dose": "2.5 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "Variable",
              "comments": "Infuse over 3 hours.",
              "originalText": "Ceftazidime-avibactam 2.5 gm IV q8h"
            },
            {
              "drugName": "Meropenem-vaborbactam",
              "dose": "4 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "Variable",
              "comments": "Infuse over 3 hours.",
              "originalText": "Meropenem-vaborbactam 4 gm IV q8h"
            },
            {
              "drugName": "Imipenem-cilastatin-relebactam",
              "dose": "1.25 gm",
              "route": "IV",
              "frequency": "q6h",
              "duration": "Variable",
              "comments": "Infuse over 30 min. For CrCl > 90 mL/min.",
              "originalText": "Imipenem-cilastatin-relebactam 1.25 gm IV q6h"
            }
          ]
        },
        {
          "regimenId": "modern-4-0-0",
          "extractedFrom": "treatment.regimens[4].recommendations[0].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Metallo-beta-lactamase (MBL) Producer",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adult"
              ],
              "labFindings": null
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Ceftazidime-avibactam",
              "dose": "2.5 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "Variable",
              "comments": "Infuse over 3 hours.",
              "originalText": "Ceftazidime-avibactam 2.5 gm IV q8h"
            },
            {
              "drugName": "Aztreonam",
              "dose": "2 gm",
              "route": "IV",
              "frequency": "q6h",
              "duration": "Variable",
              "comments": "Infuse over 3 hours.",
              "originalText": "Aztreonam 2 gm IV q6h"
            }
          ]
        },
        {
          "regimenId": "modern-4-1-0",
          "extractedFrom": "treatment.regimens[4].recommendations[1].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Metallo-beta-lactamase (MBL) Producer",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adult"
              ],
              "labFindings": null
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Cefiderocol",
              "dose": "2 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "Variable",
              "comments": "Infuse over 3 hours.",
              "originalText": "Cefiderocol 2 gm IV q8h"
            }
          ]
        },
        {
          "regimenId": "modern-5-0-0",
          "extractedFrom": "treatment.regimens[5].recommendations[0].steps[0]",
          "context": {
            "type": "directed",
            "condition": "ESBL Producer",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adult"
              ],
              "labFindings": "Urinary Tract"
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Cefepime-enmetazobactam",
              "dose": "2.5 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "Variable",
              "comments": "Recently FDA approved for complicated UTIs, including ESBL producers.",
              "originalText": "Cefepime-enmetazobactam 2.5 gm IV q8h"
            },
            {
              "drugName": "Plazomicin",
              "dose": "15 mg/kg",
              "route": "IV",
              "frequency": "q24h",
              "duration": "Variable",
              "comments": "For complicated UTIs.",
              "originalText": "Plazomicin 15 mg/kg IV q24h"
            },
            {
              "drugName": "Fosfomycin",
              "dose": "3 gm",
              "route": "PO",
              "frequency": "x 1 dose",
              "duration": "Variable",
              "comments": "For uncomplicated cystitis only.",
              "originalText": "Fosfomycin 3 gm PO x 1 dose"
            }
          ]
        }
      ]
    }
  },
  "laboratoryData": {
    "sources": [
      "laboratoryProfile"
    ],
    "value": {
      "testingIndications": [],
      "methodologyNotes": [
        "For Polymyxins, disk diffusion and gradient diffusion methods should not be performed; MIC testing is required."
      ],
      "recommendedPanel": [
        "Cefepime should be considered a Tier 1 agent for testing and/or reporting."
      ],
      "specialTests": [],
      "reportingRules": [
        {
          "ruleType": "Conditional",
          "drug": "Cefepime",
          "condition": "Isolate demonstrates carbapenemase production.",
          "details": "Cefepime S/SDD results should be suppressed or edited and reported as resistant."
        }
      ],
      "antimicrobialBreakpoints": [
        {
          "tier": 1,
          "tierDescription": "Appropriate for routine, primary testing and reporting.",
          "agents": [
            {
              "agentName": "Ampicillin",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "10 µg",
                    "s_breakpoint": "≥ 17",
                    "i_breakpoint": "14–16",
                    "r_breakpoint": "≤ 13"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 8",
                    "i_breakpoint": "16",
                    "r_breakpoint": "≥ 32"
                  },
                  "comments": [
                    "Results of ampicillin testing can be used to predict results for amoxicillin."
                  ]
                }
              ]
            },
            {
              "agentName": "Cefazolin",
              "breakpointSets": [
                {
                  "condition": "Urine Only (Uncomplicated UTI)",
                  "diskDiffusion": {
                    "diskContent": "30 µg",
                    "s_breakpoint": "≥ 15",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≤ 14"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 16",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≥ 32"
                  },
                  "comments": [
                    "Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis."
                  ]
                }
              ]
            },
            {
              "agentName": "Amoxicillin-clavulanate",
              "breakpointSets": [
                {
                  "condition": "Uncomplicated UTI only",
                  "diskDiffusion": {
                    "diskContent": "20/10 µg",
                    "s_breakpoint": "≥ 18",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≤ 17"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 8/4",
                    "i_breakpoint": "16/4",
                    "r_breakpoint": "≥ 32/4"
                  },
                  "comments": []
                }
              ]
            },
            {
              "agentName": "Piperacillin-tazobactam",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "100/10 µg",
                    "s_breakpoint": "≥ 25",
                    "i_breakpoint": "21–24",
                    "r_breakpoint": "≤ 20"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 8/4",
                    "i_breakpoint": "16/4",
                    "r_breakpoint": "≥ 32/4"
                  },
                  "comments": []
                }
              ]
            }
          ]
        },
        {
          "tier": 2,
          "tierDescription": "Appropriate for routine, primary testing, may be reported following cascade reporting rules.",
          "agents": [
            {
              "agentName": "Cefepime",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "30 µg",
                    "s_breakpoint": "≥ 25",
                    "i_breakpoint": "19–24",
                    "r_breakpoint": "≤ 18"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 4",
                    "i_breakpoint": "8",
                    "r_breakpoint": "≥ 16"
                  },
                  "comments": [
                    "Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."
                  ]
                }
              ]
            },
            {
              "agentName": "Ertapenem",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "10 µg",
                    "s_breakpoint": "≥ 22",
                    "i_breakpoint": "19–21",
                    "r_breakpoint": "≤ 18"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 0.5",
                    "i_breakpoint": "1",
                    "r_breakpoint": "≥ 2"
                  },
                  "comments": []
                }
              ]
            },
            {
              "agentName": "Meropenem",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "10 µg",
                    "s_breakpoint": "≥ 23",
                    "i_breakpoint": "20–22",
                    "r_breakpoint": "≤ 19"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 1",
                    "i_breakpoint": "2",
                    "r_breakpoint": "≥ 4"
                  },
                  "comments": []
                }
              ]
            }
          ]
        },
        {
          "tier": 3,
          "tierDescription": "Appropriate for high-risk MDRO patients, subject to cascade reporting.",
          "agents": [
            {
              "agentName": "Ceftazidime-avibactam",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "30/20 µg",
                    "s_breakpoint": "≥ 21",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≤ 20"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 8/4",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≥ 16/4"
                  },
                  "comments": [
                    "Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."
                  ]
                }
              ]
            },
            {
              "agentName": "Meropenem-vaborbactam",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "20/10 µg",
                    "s_breakpoint": "≥ 18",
                    "i_breakpoint": "15–17",
                    "r_breakpoint": "≤ 14"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 4/8",
                    "i_breakpoint": "8/8",
                    "r_breakpoint": "≥ 16/8"
                  },
                  "comments": [
                    "If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."
                  ]
                }
              ]
            }
          ]
        },
        {
          "tier": 4,
          "tierDescription": "May warrant testing and reporting by clinician request if optimal agents in other tiers are not available.",
          "agents": [
            {
              "agentName": "Aztreonam",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "30 µg",
                    "s_breakpoint": "≥ 21",
                    "i_breakpoint": "18–20",
                    "r_breakpoint": "≤ 17"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 4",
                    "i_breakpoint": "8",
                    "r_breakpoint": "≥ 16"
                  },
                  "comments": []
                }
              ]
            },
            {
              "agentName": "Ceftriaxone",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": {
                    "diskContent": "30 µg",
                    "s_breakpoint": "≥ 26",
                    "i_breakpoint": "20–22",
                    "r_breakpoint": "≤ 19"
                  },
                  "mic": {
                    "s_breakpoint": "≤ 1",
                    "i_breakpoint": "2",
                    "r_breakpoint": "≥ 4"
                  },
                  "comments": []
                }
              ]
            },
            {
              "agentName": "Colistin or Polymyxin B",
              "breakpointSets": [
                {
                  "condition": "Standard",
                  "diskDiffusion": null,
                  "mic": {
                    "s_breakpoint": "≤ 2",
                    "i_breakpoint": "—",
                    "r_breakpoint": "≥ 4"
                  },
                  "comments": [
                    "Disk diffusion and gradient diffusion methods should not be performed."
                  ]
                }
              ]
            }
          ]
        }
      ]
    }
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobial_stewardship",
        "antimicrobialStewardship"
      ],
      "value": []
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "object"
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {}
  }
}